Streetbeat News

Regulatory

DXCM

DexCom's stock is trading higher following the announcement of FDA clearance for its product, Stelo. This regulatory approval marks a significant milestone for DexCom, potentially enhancing its market position and product portfolio.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:52 pm

FHTX

Foghorn Therapeutics Inc. (FHTX) announced its participation in the 2024 AACR Annual Meeting with presentations on its pipeline programs, including preclinical data for FHD-909, a potential first-in-class BRM selective inhibitor. The company will present data on the efficacy and safety of FHD-909 and other programs such as selective CBP and EP300 degraders, showcasing significant anti-tumor activity and long-acting degrader capabilities for up to once-a-month dosing. IND filing for FHD-909 is planned in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:51 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced it will present preclinical data on CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for r/r AML, at the AACR Annual Meeting 2024. CB-012, engineered with Caribou's CRISPR technology, shows promise in improving antitumor activity through unique genome edits.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:38 pm

INAB

IN8bio will present new preclinical data at AACR Annual Meeting 2024, showing proof-of-concept for its gamma-delta CAR platform candidate targeting CD-33 and CD-123. This platform can target cancer cells while sparing healthy tissue, potentially treating previously 'undruggable' tumors.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:32 pm

DXCM

The FDA has cleared Stelo, a glucose biosensor by Dexcom, for over-the-counter use in the US. It's designed for individuals 18 and older with Type 2 diabetes not on insulin therapy. Stelo, a small wearable sensor, provides glucose insights directly to a smartphone and is set to be available in summer 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:29 pm

SPY

USO

U.S. National Security Advisor Sullivan met with the Prime Minister of Qatar to discuss efforts aimed at securing the release of hostages held by Hamas, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:01 pm

FXI

SPY

Republican Senator Rubio proposes a new $20,000 tariff on vehicles produced by Chinese automakers, potentially impacting trade relations and the automotive industry.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 8:07 pm

ENVB

Enveric Biosciences Canada, a subsidiary of Enveric Biosciences (ENVB), has been awarded U.S. Patent #11918594 for multi-substituent psilocybin derivatives and their usage methods. This patent represents a significant advancement in the development of psychedelic-based therapeutics, potentially positioning ENVB at the forefront of this emerging field.

Portfolio Pulse from Charles Gross

March 05, 2024 | 7:58 pm

PNC

PNC Financial Services Group anticipates an additional noninterest expense due to a revised special assessment in Q1 of 2024, as per an SEC filing. The company's overall interest rate risk (IRR) position is nearly neutral, with expectations of increased net interest income (NII) benefits from repricing fixed-rate assets in the coming years.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 7:09 pm

PNC

PNC Financial Services Group anticipates an additional noninterest expense of about $130M due to a revised special assessment by the FDIC, related to the systemic risk exception invoked after the closures of Silicon Valley Bank and Signature Bank. This adjustment raises the total noninterest expense to approximately $645M for Q1 2024. The FDIC's updated estimate of assessed losses to the Deposit Insurance Fund is now $20.4 billion, up from $16.3 billion, affecting PNC and other institutions.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 7:08 pm